May 15, 2017 Market Strategies Newsletter Sample Issue

MARKET STRATEGIES NEWSLETTER

Where To Invest Newsletter

Balanced Investing Strategies To Make Money In Up Or Down Markets

A Publication of Princeton Research, Inc. (<u>www.PrincetonResearch.com</u>)

Contributing Staff: Michael King, Charles Moskowitz



Proven Trading Success

Results From Our Recent Trade Alerts:

Some Of Our WINNING TRADES In 2017

100% Profits on SPY Puts in 1 Day
163% Profits on SPY Calls in 2 Days
20% Profits on AGQ Calls in 15 Days
89% Profits on SPY Calls in 1 Day
130% Profits on GS Calls in 9 Days
217% Profits on XOM Calls in 9 Days
105% Profits on XOM Calls in 3 Days
117% Profits on GLD Calls in 3 days
62% Profits on XOM Calls in 20 days
50% Profits on PFE Calls in 2 Days
31% Profits TWTR Calls in 2 Days
316% Profits on MOS Calls in 13 Days
87% Profits on AMZN Calls in 2 Days

96% Profits on K Calls in 17 Days 16% Profits on HOG Calls in 8 Days 163% Profits on SJM Calls in 23 Days 102% Profits on AMBA Calls in 7 days 250% Profits on WTW Calls in 1 Day 128% Profits on WTW Calls in 1 Day 148% Profits on NVDA Puts in 2 Days

Previous closed out trades not listed here may be seen in previous market letters in the VIP Subscribers Members Area.

Remember, these trades are based on your participation in the Subscriber Members Only TEXTING SERVICE TO RECEIVE ALL UPDATES.

New Trades Will Be TEXTED To MEMBERS



For Free Where To Invest Your Money Now High Return Investments Trade Alerts Go To: PrincetonResearch.com/alerts.htm

SPECIAL RATES Available for VIP MEMBERSHIP

Get the lowest full membership rates available.

NOTE: This is a Sample Issue Only!

TO GET OUR TRADE ALERTS BY TEXT MESSAGE AND

THE COMPLETE VIP MEMBERS ONLY MARKET STRATEGIES NEWSLETTER ISSUES

Visit: PrincetonResearch.com/join.htm

Follow Our Marketed Weathered, Time Tested Trading Rules That PROTECT YOUR CAPITAL And SECURE PROFITS

Now you can profit from investing trade alerts from our traders with over 75 combined years of successful investing experience.

Make Money In Up Or Down Markets -- Our trading alerts balanced investing strategies are designed and proven to make money in up or down markets.

- ➤ <u>Done For You</u> All the stock options picking, research and trading analysis is done for subscribers. This is not a 'class' or a 'training course'... this is us doing ALL the work... from research to sending you a text on what to trade, along with recommended amounts...
- SAFETY We strictly follow our Tested, Market Weathered Trading Rules that are proven time and time again to protect our (and now your) investment capital from losses while effectively allowing us to Keep The Profits We Make.

So even though we trade options to get the profits you see above -- We can do it with minimal risk and Maximum Profit Potential.

You Don't Need To Learn Any Trading Skills Or Do Any Time Consuming Analysis and Tracking

+++ We DO IT ALL FOR YOU! +++

We tell you where, when and how much to trade and you get to sit back and enjoy the rewards!

The specific buy and sell trading alerts are sent directly to you by e-mail and text message. So you can get in on and cash out on our winning trades fast and at the right time.

Get Started with Any Amount - Follow our recommended trading guidelines for a \$10,000 portfolio or invest more or invest less -- Whatever you are comfortable with. Your investment is protected because **Time Tested Trading Rules PROTECT YOUR CAPITAL And KEEP YOUR PROFITS.**

Join Us Today.

Lock in the Lowest Membership Rates Available HERE



2 FOR 1 BONUS:

Your Membership includes access to both:

Trade Alerts by Text Message and e-mail AND
The Market Investing Strategies Newsletter
Full Members Only Edition

Our Where To Invest Now For Profits In Up or Down Markets Newsletter is more compact, informative, effective and quicker to read then the major, big name publications. AND there are NO ADS to wade through.

The Members Edition Newsletter is sent to you by e-mail Monday Mornings and available in the Members Area along with our archive of past issues.

A Sample of the Where To Invest Now Newsletter Information Our Members Get Follows

<u>Investing Trade Alerts</u> <u>Charles Moskowitz Discussion</u>

We have only 2 open positions in HL 6/6 calls and SJM 6/130 calls with a total of \$900 of funds in use. Over the last several weeks I have mentioned that the VIX has continued to move lower to historic lows seen only 4 times in the last several decades and that with these low values the prices on "protection" has become remarkably cheap. I also said that this has created an opportunity for us to trade short-dated SPY options that are close to or "at the money" since the premiums have become almost non-existent. This week's trades took advantage of this situation. Of the 6 trades we made this week, 5 were short-dated SPY's and one was a 50% down rule liquidation (AKAM). These were very short-term (overnight or day-trade) and all were net gains.

Retail has clearly been decimated over the past several months and although it looks as if these stocks are getting cheap, I'm not so sure it's over. Macy's (M) is down 18% this week and 48% since just before Xmas shopping season and it's hard to argue how oversold it is, but while it may bounce here, the fundamental side of it looks more like a classic "value trap." All the talk about the value of its real estate is, in my opinion, a bogus argument. The main point of contention for me is the shift away from mall shopping and how the value of a mall based piece of property can be used if not for another mall based business. It's not like they can sell off the properties and build luxury condos on the footprint of an anchor tenant.

The other area of interest for me is the metals. Gold is down 6.2% from its recent highs near \$1,300/oz. while silver (down 16 days in a row) is down a whopping 13% from its recent highs near \$18.75. Both went solidly through the lower Bollinger Bands (2 standard deviations below historic price movement) and were oversold, but the silver obviously much more. We have a position in AGQ (3X ETF) but I will be looking for a place to add exposure to this trade with either more HL or the silver ETF SLV or USLV. We have an order in tonight's letter for the SLV and you'll have to watch the texting service to get additional adds... *CAM*

Investing Trade Alerts Summary \$10,000 Trading Account Trade Table

DATE	TRADES	PRICE	COST	PROCEEDS	RESULTS
05/12	Sold 10 SPY May 12 th 238.50 Calls	0.19		190	40 Gain
05/12	Sold 10 SPY May 12 th 239 Calls	0.30		300	150 Gain
	(100% up Rule)				
05/12	Bought 20 SPY May 12th 239 Calls	0.15	300		
05/11	Sold 10 SPY May 12 th \$237 Puts	0.24		240	200 Gain
05/11	Bought 10 SPY May 12 th \$237 Puts	0.04	40		
05/11	Sold 5 SPY May 12 th \$238.50 Puts	0.62		310	210 Gain
05/11	Sold 5 SPY May 12 th \$238.50 Puts	0.48		240	135 Gain
	(100% up rule + Gap)				
05/10	Bought 10 SPY May 12 th \$238.50 Puts	0.21			
05/10	Sold 5 SPY May 12 th \$239 Puts	0.32		260	5 Loss
05/09	Sold 10 SPY May 10 th \$238.50 Puts expired worthless	0.19		190	190 Gain
05/09	Sold 5 SPY May 12 th \$239 Puts	0.66		330	165 Gain
05/09	Bought 10 SPY May 12 th \$239 Puts	0.33	330		
05/08	Sold 6 AKAM June \$55 Calls	0.35		210	210 Loss
05/05	Bought 6 AKAM June \$ 55 Calls	0.70	420		
05/01	Bought 2 SJM June \$ 170 Calls	1.70	340		
05/01	Bought 2 SJM June \$ 130 Calls	1.60	320		
04/21	Bought 10 HL June 6 th \$ 6 Calls	0.24	240		

3rd Week expiration when the month is listed without a date

Previous closed out trades not listed here may be seen in previous market letters in the VIP Subscribers Members Area.

Remember, these trades are based on your participation in the Subscriber Members Only TEXTING SERVICE TO RECEIVE ALL UPDATES.



For Free Where To Invest Your Money Now High Return Investments Trade Alerts Go To: PrincetonResearch.com/alerts.htm

SPECIAL RATES Available for VIP MEMBERSHIP

Get the lowest full membership rates available.

Fundamental Analysis Stocks To Buy with Stops

Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses. All indicated on the table below, balance is critical.

Alibaba has made a few points. We are raising the stop loss price.

We have no position in Alcoa AA.

Flushing Financial FFIC fell below the 50 day price moving average on March 3rd, which was a selling opportunity. We would take profits in the Flushing Financial.

Boeing is on its way to \$ 200.

We are disappointed with Bristol Myers. We originally bought BMY at \$49.20 back on October 17th, sold on stop at 55.45 December 7th.

Sell if you are long Hecla Mining, which had been previously stopped out profitably at \$ 5.64 on Dec 15^{th.}

We took profits on ENZ but still want to buy at lower prices.

The HDGE is not relevant at this time.

Symbol	Name	Business Description	PE	P/S	MV mln	Price	Buy or Sell Limit	Stop Loss Or offset
BABA	Alibaba	China Similar to Amazon	50.67	13.21	275.5B	120.34	Bought @ \$ 111 on 4/7/17 opening	112x
AMZN	Amazon	Catalog & Mail Order	189	2.90	394B	961.35 Long	Sell on stop	910x
SIMO	Silicon Motion	Semiconductor solutions for mobile storage and communications	9.7	2.5	1.39B	49.70	39.10 01/28/17	49.40x
CIO	City Office REIT	Real Estate Investment Trust high quality Offices	292	5.8	396Mln	12.15	Re Buy at 12.12	11.50x
TPC	Tutor Perini	Construction	12	0.25	1.3B	27.50 Stopped out28.90 05/04	19.40 10/31/16	28.90x new stop loss
SAVE	Spirit Airlines	Discount Airline	13	1.6	3.6B	59.19	48.10	51.00 stopped out 3/17/17
BMY	Bristol Myers	Biopharmaceutical Products	28	5.1	94.9B	55.09	Sold at 52.80x	Bought 56.20 03/08/17
ВА	Boeing	Aerospace, commercial jetliners, military systems	14	0.85	81B	183.25	Long at 132 10/04/16	New stop loss at \$ 174
HL	Hecla Mining	Basic Materials	44	3.61	1.7B	5.75 Look for re-entry	Long at 5.24 3/3/17 Sold at \$4.84	4.85x Needs to stay above \$ 5 to be long
FFIC	Flushing Financial	Bank Holding company Savings and loans	13	3,5	592Mln	28.95	19.10 06/27	Selling opportunity
AA	Alcoa	Aluminum Processing and Technology	N/A	0.4	9.5B	31.79 No position	21.15 originally bought 2/8/16	Sold at 37.89 Re- Bought at 34.40 3/10/17
ENZ	Enzo Biochem	Life Sciences	NA	1.35	134M	9.29	Bought at 5.13 10/7/16	Sold on Opening Monday 4/3/17 Sold 8.43
BAC	Bank of America	Commercial Bank	10	2.02	165.3B	24.00	Bought at 15.42 9/30/16	23.60x stopped out on 3/21/17

HDGE	Advisor Shares	Ranger Bear ETF		8.99	Stopped out at 9.01	Must close above 8.95 to be long:
					2/10/17	3 3 3 3 3 3 3

Market Strategies Technical Information

	SUPPORT	RESISTANCE
S&P 500	23.85	2410
NASDAQ (QQQ)	138.00	139.50
Trans	89.90	92.00
DOW	20,800	21,020
TLT	120.00	122.40

\$100,000 Trading Portfolio Stock Positions and Trades

Each stock is allocated a theoretical \$5,000 share of the portfolio unless otherwise indicated.

Stock	Purchase Price	Purchase Date	Stop/Loss	Price/Date Sold	Profit/ (Loss)
YANG 500	11.97	05/01		12.80 05/08	\$ 415
AGQ 150	40.39	04/07			
VRX 200	11.08	03/16			
VRX 400	12.12	03/13			
NUGT 300	8.92	03/13			
RWM 100	50.60	11/21			
SPXU 200	22.88	11/14			
AMBA 100	63.75	10/13			
MOS 200	27.53	05/02			
EYES 500	5.04	04/04			
EYES 1000	6.49	12/28			
TWTR 200	28.51	10/28			
MOS 100	43.55	08/14			
HL 500	3.95	05/03			
SAN 600	8.40	12/16			
TEXQY 200	6.56	7/11			
REPR* 5000	0.22	10/22/12			

Recommendations will be both listed in this letter and texted to members.

Previous closed out stock and option positions can be found in past Market Strategies Newsletter issues available in the VIP Subscribers Members Area.

For those of you who do not buy puts to protect your portfolio, there are many ETF's that are the inverse of the DOW. The symbols are **DOG**, **DXD**, **SDS**,**TZA** and **RWM**, which go up when the DOW, S&P 500 and Russell 2000 go down and down when they go up. The **DZZ** goes up double when gold goes down.

Market Strategies \$100,000 Trading Account

There eight options trades;

the purchase and sale of 12 AKAM June 55 Calls bought on May 5th at \$ 0.70; sold on the 50% Loss rule at \$ 0.35 losing \$ 420.

The next six trades were all S&P trades mostly day-trades:

The first trade was on May 9th buying 20 May 12th 239 Puts @ \$ 0.33; selling Half,10 lots on the 100% Profit rule; Gaining \$ 330.

The balance was sold a later at a loss of \$ 0.01 or \$ 10.

Then on the 9th 20 SPY Puts were sold at \$ 0.19, expired worthless on the 10th, making \$ 380;

The next day 20 lots were bought again and sold the following day making profits of \$ \$ 270 and \$ 420.

On May 11th, 20 Puts were bought at \$ 0.04, sold at \$ 0.24 for a profit of \$ 400.00.

Success was found again on the 12th making profits of \$380.

The net in options trading was a gain of \$ 1750.

The stock trading made a gain of \$450.

Our hypothetical profits increased by \$ 2,200 to \$46,442.

Open trade losses decreased by \$6,962 from \$13,976 to \$7,014.

The options expire on the third Friday of each Month unless otherwise posted.

The Stock table has the following 17 positions:

AGQ, AMBA, EYES(2), HL, MOS (2), NUGT, REPR, RWM, SAN, SPXU, TEXQY, TWTR, VRX (2) and the YANG

The options call for a \$ 2,500 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically.

Money management is based on a hypothetical \$ 100,000. The 17 stock positions would cost \$ 71,620.

The four long options positions, the 10 HL June 6 Calls and the 4 SJM June 130 Calls would require \$1,800; when combined with the stock requirement of \$65,810 equals \$67,6100, which leaves excess cash of \$32,390.

The trading is hypothetical and we do not count commission costs.

Executions that have occurred at or near the open or close of trading sometimes vary from our actual numbers. For example, when something opens down and it is through our price, we take the next trade whether it is an uptick or continues lower. This sometimes results in a 50% trade that is slightly above or below the exact number.

<u>This Weeks' Economic Numbers</u> <u>Earnings Releases and Media Data</u>

Before the Open on top of the Row;

After the close below the Economics Information

e une close below une	Economics Information
MONDAY	Digital Ally DGLY (-0.26 vs -0.34) Quorum QHC (-0.49) Trivago TRVG (0.02)
	08:30 hrs Empire Manufacturing May (7.5 vs 6.2)
	16:00 hrs Net Long Term TIC Flows May (NA vs \$53.4Bln)
	Amyris AMRS (-0.08 vs -0.17) Vipshop VIPS (1.22 vs 0.16) Editas Medicine EDIT (-0.71 vs -0.80) DXP Enterprises DXPE (0.08 vs -0.35) Synchronoss Tech SNCR (0.20 vs 0.49)
TUESDAY	Home Depot HD (1.61 vs 1.44) Staples SPLS (0.17 vs 0.17) TJX TJX (0.79 vs 0.76) Dicks Sporting Goods DKS (0.54 vs 0.50) SINA SINA (0.28 vs -0.04) Virtusa VRTU (0.45 vs 0.55)
	08:30 hrs Housing Starts April (1255K vs 1215K)
	08:30 hrs Building Permits April (1270K vs 1260K)
	09:15 hrs Industrial Production April (0.3% vs 0.5%)
	09:15 hrs Capacity Utilization April (76.2% vs 76.1%)
	Baozun BZUN (0.50 vs 0.04) Jack In The Box (JACK (0.91 vs 0.85) Urban Outfitters URBN (0.16 vs 0.25) Red Robin Gourmet RRGB (0.57 vs 1.27) Acxiom ACXM 0.15 v 0.18
WEDNESDAY	American Eagle AEO (0.17 vs 0.22) Citi Trends CTRN (0.68 vs 0.60) Target TGT (0.91 vs 1.29) QIWI QIWI 14.92 vs 20.41 Jamba JMBA (-0.07 vs -0.28)
	07:00 hrs MBA Mortgage Applications Index 05/12 (NA vs 2 49/)
	07:00 hrs MBA Mortgage Applications Index 05/13 (NA vs 2.4%) 10:30 hrs Crude Inventories 05/13 (NA vs -5.25 Mln Bbls)
	Cisco Systems CSCO (0.58 vs 0.57) Flowers Foods FLO (0.25 vs 0.28) L Brands LB (0.30 vs 0.59) Rexnord RXN (0.33 vs 0.37) ZTO Synopsys SNPS (0.86 vs 0.81) ZTO Express ZTO (0.67) Stein Mart SMRT (0.22 vs 0.30) Kadmon Holdings KDMN (-0.57)
THURSDAY	Alibaba BABA (0.67 vs 0.47) CAE CAE (0.29 vs 0.27) Perrigo PRGO (1.82 vs 1.80) Ralph Lauren RL (0.78 vs 0.88) Wal-Mart Stores WMT (0.96 vs 0.98)
	08:30 hrs Initial Claims 05/20 (240K vs 236K)
	08:30 hrs Continuing Claims 05/13 (NA vs 1918K)
	08:30 hrs Philadelphia Fed May (18.5 vs 22.0)
	10:00 hrs Leading Indicators April (0.4% vs 0.4%)
	10:30 hrs Natural Gas Inventories 05/13 (NA vs 45 bcf)
	Applied Materials AMAT (0.76 vs 0.74) Gap GPS (0.29 vs 0.32) McKesson MCK 3.01 vs 2.44 Ross Stores ROST (0.80 vs 0.73) Salesforce.com CRM (0.26 vs 0.24)

FRIDAY	Campbell Soup CPB (0.64 vs 0.65) Deere DE (1.66 vs 1.56) Destination XL Group DXLG (-0.04 vs 0.00) Foot Locker FL (1.38 vs 1.39)
	The U.S. Oil Rig Count increased by 6 Rigs to 703. One year ago there were 354 rigs in use. The Nat Gas Rig count increased to a total of 171 and there is two rigs listed as miscellaneous totaling a US rig count of 876. Crude closed lower for a second week at \$46.22, down \$3.13 Natural Gas closed the week off \$0.01 or -0.3%, At \$3.226

You Don't Need To Learn Any Trading Skills Or Do Any Time Consuming Analysis and Tracking

+++ We DO IT ALL FOR YOU! +++

We tell you where, when and how much to trade and you get to sit back and enjoy the rewards!

The specific buy and sell trading alerts are sent directly to you by e-mail and text message. So you can get in on and cash out on our winning trades fast and at the right time.

Get Started with Any Amount - Follow our recommended trading guidelines for a \$10,000 portfolio or invest more or invest less -- Whatever you are comfortable with. Your investment is protected because **Time Tested Trading Rules PROTECT YOUR CAPITAL And KEEP YOUR PROFITS.**

Join Us Today.

Lock in the Lowest Membership Rates Available HERE

Undervalued Small Cap Stocks

Lower Priced stocks that look to be a buy: Lower Capitalized Companies with Great Potential

("RMS" or the "Company") is pleased to announce that the umbrella organization of the public health insurance in Germany approved the FREEDOM60® Infusion System for reimbursement. The FREEDOM60® System was registered January, 31st 2017 and listed in the Medical Device Registry in the category mechanical infusion pumps. It is the ONLY device of its kind registered within Germany.

In partnership with **ContraCare** GmbH, a leader in Germany for Contract Management (reimbursement services) and managed Care, the RMS FREEDOM60[®], FreedomEdge[®], RMS Precision Flow Rate Tubing[™] and RMS HIgH-Flo Subcutaneous Safety Needle Sets[™] are now poised to dominate this growing market in Europe.

Torsten Kühn, Chief Executive Officer of ContraCare, commented "as a premium service provider in Germany's health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and

high-quality HIgH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany's public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement."

Eric Bauer, Chief Operating Officer of RMS commented, "It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life."

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60[®] and our latest Freedom Edge[®] Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC[®] line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Pumps, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

Enzo Biochem (ENZ: \$ 9.29)*

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year it was up 54.22% versus the Dow Jones +13%. The relative strength index was 53.41 which is neutral and short interest declined to 827,800 shares. However the RSI has climbed to over 80 and is now 69.08 on April 1st, 2017. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court.

What do I look for in 2017? The market will be interesting in the first half with the Government transition to a new administration. Abbots Summary Judgement request was denied by the Court but the trial date has yet to be set. At some point the 2nd Court of Appeals will rule on Enzo's appeal on the CT. Courts reversal of the Jury's decision in the Enzo vs. Apalera Case. The market is giving no value, win or lose, to this decision. The stake is \$65 million with no adverse effect if ruled against Enzo. Enzo should again outperform the Dow and S&P in 2017.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.

When the company gets a 500 million dollar market cap (\$10.63) they will qualify for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIO (0.27)*

Recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is "bottlenecked" by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking - the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called **pressure cycling technology, or PCT**, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch ("psi") or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and

specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid ("*DNA*"), ribonucleic acid ("*RNA*"), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler[®], and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction ("*PULSE*") tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their **PCT Sample Preparation System** ("*PCT SPS*").



The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;
 - Pathogen inactivation (useful in vaccine development, infectious disease research, and more);
- Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);
 - and immunodiagnostics (useful in the development and detection of biomarkers).

INTELLECTUAL PROPERTY

PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.

NightFood, Inc. (NGTF 0.27)* Has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer

and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.

People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested.

Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the NightFood bar line, and also manufacturing products in different snack formats, like ice cream or "bites"

Consumers spend over \$50 billion/year on night-time snacks...over \$1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies,

Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We've seen it happen with low-carb, we've seen it happen with gluten-free. Can it happen with nighttime snacking as well?

Leo Motors (LEOM: \$ 0. 12)* has patents for the electric battery industry which we will be writing about in upcoming weekly reports. They have developed a lithium battery that can operate vehicles in sub-zero climates. Their subsidiary LGM has developed battery technology supported by the Korean government to make it possible to use electric battery technology for fishing boats. They have a cartridge system which is a light-weight replacement method of swapping electric batteries.

Fishing has been harmed by the noise and oil leaks from internal combustion engines. LGM has solved that problem and besides eliminating the toxic problem, operating costs are reduced by 25%.

In addition they have a special patent for averting electric hazards and shocks. Leo developed the Internet of Things for e-boats which is networked and connected with an Android Operating System. Leo's power supply system is CAN (Controller Area Network) based, which enables mobile diagnostics between mobile devices and boats using the Leo technology.

Leo is developing a battery swap system for Kalmado in Puerto Princesa, Philippines, a world famous tourist attraction, which is focused on green energy. They will be converting 100 boats as the environment is expected to become 100% free of the toxicity from internal combustion engines. Also, Leo has developed a battery swap system for Go-Karts to be used in malls in China, Korea and Myanmar.

Leo Motors has a new carbon nanotube battery power pack that functions and supplies full power in extreme low temperatures such as below 49 degrees without the need for grid electricity.

<u>Skinvisible (SKVI: \$ 0.025</u>): they have developed skin care products using its patented Invisicare polymer delivery systems and transdermal cannabis products from hemp-derived CBD, with its new developments to include cannabinoids from marijuana CBD and THC.

Rule 17B Attestations and Disclaimers

Princeton Research, Inc. has approximately 2,581,578 shares of AIVN both free and restricted and represents them for Investor relations. Princeton also has about 40,000 shares of TXGE. Princeton is paid \$ 1,500 per month from RMS Medical Products. Princeton has bought 81,100 shares of RMS Medical Products. Princeton was paid \$ 2,500 to write a report on Xinergy. Princeton has signed a contract with CBLI to be paid \$ 2500 for July and August for investor relations. Princeton has been engaged by Target Energy. No contract is currently in place. Princeton was paid about 500,000 restricted shares of Leo Motors.

When there is no movement in penny stocks, even though there is none or very small losses, we will liquidate (sold AIVN on stop) even though we like the company, if money is needed for better opportunities.

We now believe REPR represents upside opportunity. The Target ADR trades at about \$ 4.50 in U.S. vs 0.05 in Australia. Princeton owns 400,000 Australia shares and about 900 U.S. ADR's.

Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this e-mail issue. Princeton may buy or sell its free-trading shares in companies it represents at any time.

CONTACT

Please Direct All Inquiries To:

Mike King (702) 650-3000 mike@princetonresearch.com

Charles Moskowitz (781) 826-8882 CAM@MoneyInfo-LLC.com

Princeton Research 3887 Pacific Street, Las Vegas, Nevada 89121 Fax: (702) 697-8944

www.PrincetonResearch.com